Protocol Ledger

NCT04768881 · Phase II · TERMINATED

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Interventional Phase II clinical trial protocol NCT04768881 sponsored by Karyopharm Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-12 Enrollment: 15 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04768881
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)15 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04768881
Protocol FieldVerified Registry Value
NCT IdentifierNCT04768881
Consolidated Lead SponsorKaryopharm Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment15 participants (ACTUAL)
Registered Start Date2021-05-12
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04768881
Hospital Research SiteLocationSite Profile
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->
Rutgers Cancer Institute of New JerseyNew Brunswick, NJOpen Hospital Dossier ->
Memorial Sloan Kettering Cancer CenterNew York, NYOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI